FTMI-TBPET-PSMR 2026 Valencia

Session

Session 12: PSMR-Applications

13 May 2026, 16:40

Valencia Hotel Las Arenas

Conveners

Session 12: PSMR-Applications

• Casper Beijst

70. Sponsor Keynote: TERAPET:Translating Advanced Detection Technologies into Clinical Practice: The Terapet Portfolio

Christina Valgreen

13/05/2026, 16:40

Platinum sponsor talk

56. SPECT image reconstruction using PET priors via 3D Diffusion with Posterior Sampling for ultra-low count projections for alpha therapy dosimetry

Alejandro López Montes (Inselspital Bern, University of Bern)

13/05/2026, 17:00

Background: Alpha-particle radiopharmaceutical therapy (α-RPT) is a promising treatment modality for cancers such as metastatic castration-resistant prostate cancer. Compared to β-emitters (e.g. ¹⁷⁷Lu), α-emitters such as ²²⁵Ac deliver high linear energy transfer over a short range, enabling effective tumour cell killing while sparing surrounding tissue. However, clinical translation is...

23. Cross-Modal Transfer of MRI Foundation Model Embeddings Enables Multimodal FPIA PET–MRI Prediction of IDH Mutation in Glioma

Marianna Inglese (Department of Biomedicine and Prevention - University of Rome Tor Vergata)

13/05/2026, 17:20

Accurate non-invasive prediction of isocitrate dehydrogenase (IDH) mutation status remains a major challenge in glioma imaging. Although magnetic resonance imaging (MRI) provides valuable structural and functional information, conventional radiological features lack consistent predictive power across datasets. Recent advances in foundation models trained on large-scale MRI datasets offer a new...

22. Spatiotemporal FPIA PET–MRI Phenotyping Reveals Oligoclonal Metabolic Niches and Vascular Remodeling in Brain Metastases

Marianna Inglese (Department of Biomedicine and Prevention - University of Rome Tor Vergata)

13/05/2026, 17:40

Intracranial metastatic disease (IMD) remains a major cause of cancer-related morbidity and mortality, yet the metabolic heterogeneity of brain metastases is poorly characterized in vivo. Conventional imaging typically treats lesions as metabolically homogeneous entities, potentially obscuring biologically meaningful tumor subregions. Here, we present a multimodal imaging framework integrating...

12. Quantifying Baseline Relative Permeability between PET and DCE-MRI using a DCE Flow Phantom with Total-Body PET

Robbie Haynes (School of Physics & Astronomy, University of Edinburgh, United Kingdom)

13/05/2026, 18:00

Introduction:
Positron emission tomography (PET) and dynamic contrast-enhanced MRI (DCE-MRI) probe complementary transport processes; $^{18}$F-FDG can undergo carrier-mediated uptake, while gadolinium chelates distribute via passive diffusion. Imaging both modalities in a shared permeability phantom isolates passive transport, allowing the establishment of a baseline permeability ratio...